Effect of decreased renal function on poor oncological outcome after radical cystectomy

被引:3
作者
Kim, Dongsu [1 ]
Nam, Wook [2 ]
Kyung, Yoon Soo [1 ]
You, Dalsan [1 ]
Jeong, In Gab [1 ]
Hong, Bumsik [1 ]
Hong, Jun Hyuk [1 ]
Ahn, Hanjong [1 ]
Lim, Bumjin [1 ,3 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
[2] Univ Ulsan, Gangneung Asan Hosp, Dept Urol, Coll Med, Kangnung, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
关键词
Bladder cancer; Glomerular filtration rates; Patient outcome assessment; INVASIVE BLADDER-CANCER; CHRONIC KIDNEY-DISEASE; CISPLATIN-BASED CHEMOTHERAPY; TRANSITIONAL-CELL CARCINOMA; GLOMERULAR-FILTRATION-RATE; RISK-FACTOR; RECURRENCE; PROGRESSION; ELIGIBILITY; PATTERNS;
D O I
10.4111/icu.20230063
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To evaluate the impact of preoperative renal impairment on the oncological outcomes of patients with urothelial carci-noma who underwent radical cystectomy.Materials and Methods: We retrospectively reviewed the medical records of patients with urothelial carcinoma who underwent radical cystectomy from 2004 to 2017. All patients who underwent preoperative 99mTc-diethylenetriaminepentaacetic acid renal scintigraphy (DTPA) were identified. We divided the patients into two groups according to their glomerular filtration rates (GFRs): GFR group 1, GFR>_90 mL/min/1.73 m2; GFR group 2, 60<_GFR<90 mL/min/1.73 m2. We included 89 patients in GFR group 1 and 246 patients in GFR group 2 and compared the clinicopathological characteristics and oncological outcomes between the two groups.Results: The mean time required for recurrence was 125.5 & PLUSMN;8.0 months in GFR group 1 and 85.7 & PLUSMN;7.4 months in GFR group 2 (p=0.030). The mean cancer-specific survival was 131.7 & PLUSMN;7.8 months in GFR group 1 and 95.5 & PLUSMN;6.9 months in GFR group 2 (p=0.051). The mean overall survival was 123.3 & PLUSMN;8.1 months in GFR group 1 and 79.5 & PLUSMN;6.6 months in GFR group 2 (p=0.004).Conclusions: Preoperative GFR values in the range of 60<_GFR<90 mL/min/1.73 m2 are independent prognostic factors for poor recurrence-free survival, cancer-specific survival, and overall survival in patients after radical cystectomy compared with GFR val-ues of >_90 mL/min/1.73 m2.
引用
收藏
页码:346 / 352
页数:7
相关论文
共 30 条
  • [1] Baseline Renal Function Status Limits Patient Eligibility to Receive Perioperative Chemotherapy for Invasive Bladder Cancer and Is Minimally Affected by Radical Cystectomy
    Canter, Daniel
    Viterbo, Rosalia
    Kutikov, Alexander
    Wong, Yu-Ning
    Plimack, Elizabeth
    Zhu, Fang
    Oblaczynski, Megan
    Berberian, Raffi
    Chen, David Y. T.
    Greenberg, Richard E.
    Uzzo, Robert G.
    Boorjian, Stephen A.
    [J]. UROLOGY, 2011, 77 (01) : 160 - 165
  • [2] Recurrence of high-risk bladder cancer: A population-based analysis
    Chamie, Karim
    Litwin, Mark S.
    Bassett, Jeffrey C.
    Daskivich, Timothy J.
    Lai, Julie
    Hanley, Jan M.
    Konety, Badrinath R.
    Saigal, Christopher S.
    [J]. CANCER, 2013, 119 (17) : 3219 - 3227
  • [3] Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan
    Chang, Chung-Hsin
    Yang, Cheng-Ming
    Yang, An-Hang
    [J]. CANCER, 2007, 109 (08) : 1487 - 1492
  • [4] Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary
    Chang, Sam S.
    Bochner, Bernard H.
    Chou, Roger
    Dreicer, Robert
    Kamat, Ashish M.
    Lerner, Seth P.
    Lotan, Yair
    Meeks, Joshua J.
    Michalski, Jeff M.
    Morgan, Todd M.
    Quale, Diane Z.
    Rosenberg, Jonathan E.
    Zietman, Anthony L.
    Holzbeierlein, Jeffrey M.
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (09) : 621 - +
  • [5] UROLOGIC CANCERS IN UREMIC PATIENTS
    CHEN, KS
    LAI, MK
    HUANG, CC
    CHU, SH
    LEU, ML
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 25 (05) : 694 - 700
  • [6] Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder
    Dash, Atreya
    Galsky, Matthew D.
    Vickers, Andrew J.
    Serio, Angel M.
    Koppie, Theresa M.
    Dalbagni, Guido
    Bochner, Bernard H.
    [J]. CANCER, 2006, 107 (03) : 506 - 513
  • [7] FLEMING JS, 1987, EUR J NUCL MED, V13, P250, DOI 10.1007/BF00252602
  • [8] How I treat bladder cancer in elderly patients
    Galsky, Matthew D.
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2015, 6 (01) : 1 - 7
  • [9] Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer
    Grossman, HB
    Natale, RB
    Tangen, CM
    Speights, VO
    Vogelzang, NJ
    Trump, DL
    White, RWD
    Sarosdy, MF
    Wood, DP
    Raghavan, D
    Crawford, ED
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (09) : 859 - 866
  • [10] Preoperative chronic kidney disease predicts poor oncological outcomes after radical cystectomy in patients with muscle-invasive bladder cancer
    Hamano, Itsuto
    Hatakeyama, Shingo
    Iwamura, Hiromichi
    Fujita, Naoki
    Fukushi, Ken
    Narita, Takuma
    Hagiwara, Kazuhisa
    Kusaka, Ayumu
    Hosogoe, Shogo
    Yamamoto, Hayato
    Tobisawa, Yuki
    Yoneyama, Tohru
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Koie, Takuya
    Ito, Hiroyuki
    Yoshikawa, Kazuaki
    Kawaguchi, Toshiaki
    Ohyama, Chikara
    [J]. ONCOTARGET, 2017, 8 (37) : 61404 - 61414